Post Neurosurgical Meningitis due to Colistin Heteroresistant Acinetobacter baumannii

Introduction: Recently Acinetobacter baumannii isolates have emerged as a problematic infectious agent that causes meningitis in neurosurgical patients. Colistin has been used successfully for the treatment of A. baumannii meningitis but colistin resistant isolates have been reported worldwide. Case Presentation: Two isolates of A. baumannii were cultured during a five-day period from cerebrospinal fluid (CSF) samples of a 20-year-old man with a gunshot trauma in the abdomen, which had exited from his back. Antimicrobial susceptibility tests of isolates were performed. Multiplex PCR was performed for detection of bla(OXA-23-like), bla(OXA-24-like) and bla(OXA-58-like) genes. Metallo-beta-lactamase genes such as: bla(VIM), bla(IMP), bla(SPM) and bla(NDM) were sought by singleplex PCR. In order to evaluate the genetic relationship, two isolates were examined by the repetitive extragenic palindromic-polymerase chain reaction (REP_PCR) method. Conclusions: E-test results showed that the isolates were sensitive to colistin and tigecycline with minimum inhibitory concentration of (MIC) 0.25 mu g/mL and 1.5 mu g/mL, respectively. Secondly the isolates were resistant to colistin with MIC > 256 mu g/mL but remained sensitive to tigecycline with MIC 1.5 mu g/mL. On the basis of the multiplex PCR, both of the isolates were positive for blaOXA-23-like. Other investigated genes such as bla(OXA-24-like), bla(OXA-58-like), bla(VIM), bla(IMP), bla(SPM) and bla(NDM) were negative. REP-PCR results showed that two isolates were derived from a single strain and both were the same. The results of our study revealed that the firs isolate of A. baumannii was colistin heteroresistant and was changed to completely resistant during therapy. Diagnosis and treatment of A. baumannii meningitis is very important and to avoid treatment failure we suggest that all A. baumannii isolates obtained from CSF should be evaluated properly for colistin heteroresistance.